Project Grant HT94252311058
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$3.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02118, USA
Similar Awards
The Department of the Army Medical Command awarded a $472,560 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The funding supports research aimed at "Targeting Mutant Protein Degradation for Therapeutic Intervention of Genetic FSGS", which refers to focal segmental glomerulosclerosis, a type of kidney disease. The grant has a performance period from January 1, 2025 to December...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $2,531,888 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study "CORRECTING CYTOSKELETAL ABNORMALITIES AND PODOCYTE VULNERABILITY IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS." The 4-year award, starting on May 1, 2024, supports Bidmc's research aimed at improving treatments for this kidney disorder. As a leading academic medical center, Bidmc has an...
The Defense Health Agency awarded a $522,477 Project Grant to Boston Medical Center Corporation (BMC) under the Military Medical Research and Development program (CFDA 12.420). The funding will support research to define genetic vulnerabilities in pancreatic neuroendocrine tumors that rely on the alternative lengthening of telomeres pathway. This 3-year project grant runs from August 1, 2023 to July 31, 2026. A sub-award of an unspecified amount was provided to the Trustees of Boston...
This Cooperative Agreement award in the amount of $532,228 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports a clinical trials site application for the Kidney Cancer Research Consortium at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The funding will enable Bidmc, a prominent academic medical center and teaching hospital affiliated with Harvard Medical School, to...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
This federal Project Grant award of $1,723,552.00, awarded on September 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The grant funds research targeting specific long non-coding RNAs (lncRNAs) to modulate the TSP1-dependent immune microenvironment vulnerabilities in advanced thyroid cancer. The research aims to...
This federal Project Grant award of $518,700.00 was made by the Defense Health Agency on July 1, 2024 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The award is part of the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public. The funding will support Bidmc's project titled "EXPLOITING DISRUPTION IN TRANSCRIPTIONAL...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $330,000 project grant to Trustees of Boston University, doing business as the Boston University Medical Campus. The grant, awarded on March 15, 2024, will fund research to enhance lymphatic function using transplanted muscle cells after bacterial infection. The research aims to improve medical care for military service members, veterans, and their families. Boston University, a leading...